IMGT®, the international ImMunoGeneTics® information system founded in 1989 by Marie-
Paule Lefranc (Université de Montpellier and CNRS), marked the advent of …

Amplicon-based next-generation sequencing (NGS) of immunoglobulin (IG) and T-cell
receptor (TR) gene rearrangements for clonality assessment, marker identification and …

Twenty years after landmark publications, there is a consensus that the somatic
hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable (IGHV) gene is …

Assessment of clonality, marker identification and measurement of minimal residual disease
(MRD) of immunoglobulin (IG) and T cell receptor (TR) gene rearrangements in lymphoid …

Current diagnostic standards for lymphoproliferative disorders include multiple tests for
detection of clonal immunoglobulin (IG) and/or T-cell receptor (TCR) rearrangements …

Immunoglobulin heavy chain (IGH) clonality testing by next-generation sequencing (NGS)
offers unique advantages over current low-throughput methods in the assessment of B-cell …

Ultra-deep next-generation sequencing has emerged in recent years as an important
diagnostic tool for the detection and follow-up of tumor burden in most of the known …

Cancer is characterized by an extremely complex biological background, which hinders
personalized therapeutic interventions. Precision medicine promises to overcome this …

Natalizumab (NTZ) and autologous hematopoietic stem cell transplantation (AHSCT) are
two successful treatments for relapsing-remitting multiple sclerosis (RRMS), an autoimmune …

Minimal residual disease (MRD) is the most important independent prognostic factor in
acute lymphoblastic leukemia (ALL). Since it has been implemented into in treatment …